Abstract. An indirect fluorescent antibody (IFA) test was developed using a novel format of Borrelia burgdorferi organisms adhered to a monolayer of cultured endothelial cells derived from an equine tumor. Sensitivity and specificity of the new IFA test for detecting anti-B. burgdorferi antibodies were evaluated using sera from dogs inoculated with live B. burgdorferi or vaccinated with B. burgdorferi bacterin or leptobacterins and from unvaccinated specific-pathogen-free (SPF) dogs. To compare the new IFA test with existing tests, serum samples were submitted to independent laboratories to be tested by enzyme-linked immunosorbent assay (ELISA) and a traditional IFA test. Samples were also tested with 2 commercially available membrane-bound ELISA kits. Both Borrelia-inoculated dogs and dogs vaccinated with B. burgdorferi bacterin developed levels of antibody detectable by the new IFA test. Dogs vaccinated with a combination canine vaccine or leptobacterin for food animal use developed detectable levels of antibody against Leptospira but remained seronegative for Borrelia by the new IFA test, as did the unvaccinated SPF dogs. The new IFA test was sensitive, detecting antibodies against B. burgdorferi as early as 7 days postinoculation. It was also specific, showing no cross-reactivity with anti-Leptospira antibodies induced by vaccination with leptobacterins. The new IFA test compared favorably with both the standardized traditional IFA test and ELISA. Results from both membrane-bound ELISA kits were not consistent when compared with each other or with the new IFA test. The new IFA test had low nonspecific fluorescence, which made it easier to evaluate and reduced the human error and variability of test results.
The diagnosis of infection with Borrelia burgdorferi has been difficult and controversial. The first documented cases of human infection occurred in 1977 in Old Lyme, Connecticut, and initially were misdiagnosed as juvenile rheumatoid arthritis. 18 Investigations of the Connecticut epidemic eventually led to the isolation of the organism in 1982. 3 In 1984, the first case of B. burgdorferi infection in a dog was reported. 11 The isolation of B. burgdorferi from clinical specimens can be a lengthy and unrewarding approach to diagnosis; 8 therefore, much attention has been given to developing auxiliary diagnostic tests.
Among the first techniques applied to Lyme disease testing were the indirect fluorescent antibody (IFA) test 2 and the enzyme-linked immunosorbent assay (ELISA). 14, 16 With human serum, both tests have been considered sensitive for late-stage disease but relatively insensitive in early disease, and both tests have shown cross-reactivity with other spirochete disease agents. 16 Other methods have been applied to testing for Lyme disease, including antigen capture, 4 polymerase chain reaction 6,17 and western blotting; 12,15 however, the IFA test and ELISA remain the most commonly used.
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Received for publication April 28, 1995. rified flagella 7 and a recombinant flagellar protein 3 used as test antigens improved the sensitivity and increased the specificity of the ELISA for human testing. When canine serum was tested using the IFA test, ELISA, and western blotting, the IFA test was equally specific as but less sensitive than the ELISA, whereas western blotting showed some indication of cross-reactivity with antibodies against Leptospira and immune-mediated diseases.
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The utility of serologic test results in arriving at a diagnosis is limited by the inherent deficiencies of the existing tests regarding sensitivity and specificity. The lack of test standardization further complicates the interpretation of test results. A proficiency testing program for Lyme disease serology conducted among 45 laboratories indicated a high rate of false-negative results and a considerable rate of false-positive results.
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Most alarming, however, was the variability of results, both among different laboratories and within a given laboratory. The reproducibility of test results was poor, and improvement in the sensitivity and specificity of tests and test standardization was recommended. The purpose of this study was to evaluate the sensitivity and specificity of a novel IFA test for detecting antibodies against B. burgdorferi in canine serum.
Materials and methods
Antigen slides. Eleventh passage JD-1 strain B. burgdorferi organisms were grown at 35 C in Barbour-Stoenner-Kelly medium prepared as previously described. 9 The organisms were harvested in late log phase or early stationary phase growth by centrifugation a at 1,200 x g for 15 min and then washed twice in sterile phosphate buffered saline (PBS). The washed organisms were resuspended in M-199 tissue culture medium b supplemented with 20% fetal calf serum. c The bacterial suspension was counted in a Petroff-Hausser chamber, d and the density was adjusted to approximately 3 x 10 7 organisms/ml. The suspension was refrigerated for 1-7 days before use.
Eight-well slides e were seeded with equine endothelial (ET) cells. The ET cell line was originally established from a muzzle tumor of a foal and has been maintained through more than 200 passages in this laboratory over the past 4 yr. The ET cells were cultured in Eagle minimum essential medium b supplemented with 2 mM L-glutamine, 10 mM HEPES buffer, and 10% fetal calf serum, 0.2 ml/well. Cell cultures were incubated in a humid 5% CO 2 environment at 37 C until the cells covered 50-75% of each chamber surface (ca. 24 hr). At this time, the medium was decanted, and 0.2 ml of the suspension of B. burgdorferi in M-199 (ca. 6 x 10 6 organisms) was added to each chamber and the slides were incubated for 4 hr. The chamber assembly was removed from the slides and washed in sterile PBS and fixed in acetone at room temperature for 10 min and stored at -20 C until used.
Test procedure. Slides were removed from the freezer, allowed to warm to room temperature, and then washed. The washing procedure consisted of dipping the slides several times in water, immersing in sterile 0.5 M carbonate buffer (pH 9) for 5 min, then dipping in water as before, and allowing to air dry. A stock of negative control serum was obtained from a specific-pathogen-free (SPF) dog and was included with all test runs at a dilution of 1:8. Test sera were diluted in sterile endotoxin-free PBS in 1 of 2 ways: 1) an initial 1:10 dilution followed by serial 5-fold dilutions or 2) an initial 1:8 dilution followed by serial 2-fold dilutions. A 25-µl aliquot of each dilution was placed onto separate squares of the antigen slide and spread over the whole surface of the square with a clean glass rod. The slide then was incubated in a humid chamber at room temperature for 30 min, washed, and allowed to air dry. A 25-µl aliquot of anti-dog IgGfluorescein isothiocyanate conjugate f diluted 1:250 in PBS with 0.002% Evans blue g was added to each square and spread as before, and the slide was incubated for 30 min in the dark. After this incubation, the slide was washed and air dried. Two drops of a mounting medium, consisting of PBS with 10% glycerol, were then placed on the slide and a cover glass was added. The slide was examined using a microscope with a fluorescent light source h at a magnification of 200 x . Test sera. Negative control sera were obtained from 17 SPF dogs: 3 vaccinated subcutaneously with a combination canine vaccine i containing leptobacterin (serovars canicola and icterohaemorrhagiae), 4 vaccinated subcutaneously with a leptobacterin for food animal use j (serovars canicola, icterohaemorrhagiae, haardjo, grypotyphosa, and pomona), and 10 unvaccinated. Positive control sera were obtained from 16 dogs: 6 inoculated intradermally with a single dose of approximately 5 x 10 12 JD-1 strain B. burgdorferi organisms, 5 that received a single dose of canine B. burgdorferi bacterin, k and 5 that received 2 doses of this bacterin 3 wk apart. Serum was obtained from these control dogs periodically and tested using the new IFA test.
Test comparison. Of the positive control samples from Borrelia-inoculated dogs, 6 were submitted to a commercial laboratory for assay by a traditional IFA test (Louisiana Veterinary Medical Diagnostic Laboratory, Baton Rouge, LA) and 2 for testing by ELISA (Connecticut Agricultural Experiment Station, New Haven, CT). Seven canine serum samples were obtained with known anti-B. burgdorferi titers as tested by a standardized ELISA (performed at the Connecticut Agricultural Experiment Station, New Haven, CT). These samples were assayed blindly using the new IFA test. Serum samples from all dogs vaccinated against Leptospira were submitted to a commercial laboratory for determination of anti-leptospira antibody titers by agglutination test (Charles S. Roberts Veterinary Diagnostic Laboratory, Auburn, AL). (Fig. 1A) . Slides treated with negative sera showed low background fluorescence of cells, but no spirochetes were visible (Fig. 1 B) . The new IFA test compared favorably with both the standardized ELISA (Table 1 ) and IFA test (Table 2) . No false-positive or false-negative results were observed, and the new IFA titers generally were within 2 or 3 dilutions of the ELISA titers.
Negative control dogs vaccinated with either the combination canine vaccine or the leptobacterin for food animal use developed measurable titers of anti- body against the different serovars of Leptospira but remained seronegative for B. burgdorferi (data not shown). None of the 10 unvaccinated dogs developed detectable antibody against B. burgdorferi (data not shown).
Positive control dogs inoculated with B. burgdorferi had detectable levels of antibody against the spirochete as early as 7 days after inoculation; all seroconverted within 14 days of inoculation and most remained seropositive throughout the monitoring period. Dogs vaccinated with the B. burgdorferi bacterin had detectable levels of antibody by day 28 postvaccination and remained seropositive throughout the monitoring period (Table 3) .
Results from both the CITE and the D-TEC kits were inconsistent with each other and with those obtained from the IFA test. Of the 46 control samples tested by all 3 methods, the IFA test correctly identified all samples, indicating 100% sensitivity and specificity. CITE had 6 false-positive and 5 false-negative tests and D-TEC had 1 false-positive and 3 false-negative tests. Using these data, the calculated sensitivity and specificity of CITE were 72% and 78.6% and of D-TEC were 83.3% and 96.4%, respectively (Table 4) .
Discussion
The new IFA test reported here has distinct advantages over traditional IFA tests for detection of antibodies against B. burgdorferi. Antigen slides for traditional IFA tests are prepared by drying 1 drop of a suspension of B. burgdorferi in PBS onto a glass slide. With this format, it often is difficult with negative samples to determine whether there really is no fluorescence or if the microscope is not focused in the proper plane. The presence of a background of cultured cells in the new IFA makes it possible to quickly and accurately determine the right plane of focus. Low background fluorescence makes it easy with positive samples to visualize the specific fluorescence and characteristic morphology of the spirochetes. With negative samples, the spirochetes are simply not visible. There are very few refractile artifacts that can be mistakenly identified as spirochetes, as is often times the case with salt crystals in the traditional IFA format. All of these elements together make the new IFA test easy to in-terpret, with clear-cut results requiring less subjective judgment than did previous tests. The result is decreased human error in test evaluation, leading to greater reproducibility of test results.
The new IFA test detected antibodies as early as 7 days after inoculation with B. burgdorferi, and there was no cross-reactivity with antibodies against Leptospira or any of the other infectious agents in the combination canine vaccine. These results indicate that the new IFA has high sensitivity and specificity, which is supported by the results of its comparison with 2 standardized tests. Moreover, the results from control samples revealed 100% sensitivity and 100% specificity for the new IFA test. Even though the number of control samples evaluated was relatively small, the data indicate that a high degree of reliability could be anticipated if the new IFA were used as a routine serologic test.
The inconsistent results obtained with the 2 membrane-bound ELISA kits indicate that they may be misleading if used as screening tests. In testing the 46 control samples, the kits gave both false-positive and false-negative results. CITE had 24% false results, whereas D-TEC performed somewhat better, giving only 8% erroneous results. Because the results from the two kits were inconsistent with those of the IFA test and with each other, it seems likely that the sensitivity and specificity of both CITE and D-TEC kits leave something to be desired.
The new IFA test is sensitive, specific, and simple to perform. The novel use of B. burgdorferi adhered to cultured cells in this test makes it easier to interpret than traditional IFA tests. Use of this IFA test could increase the reliability of Lyme disease serology.
